✨ Free AI Report
SCYNEXIS, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research SCYNEXIS, Inc.
Company Research

SCYNEXIS, Inc.: Business Overview, Financials & Competitive Analysis

SCYNEXIS, Inc. scores 4/10 on the AskCyborg Cyborg Score (Challenged). Early-stage antifungal biotech with promising novel mechanism but pre-commercial status and near-term cash concerns require successful clinical execution and partnership support. Revenue declined dramatically to $3.7M in 2024 from higher prior year levels, with negative operating income of -$37.1M. Despite strong partnership relationships and a novel drug class, the company.

What is SCYNEXIS, Inc.'s industry? SCYNEXIS, Inc. (scynexis.com) operates in Biopharmaceuticals / Antifungal Therapeutics. AskCyborg classifies SCYNEXIS, Inc. under Biopharmaceuticals / Antifungal Therapeutics in its company registry.

SCYNEXIS is a biotechnology company committed to positively impacting patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The company offers BREXAFEMME ...

4/ 10Challenged

Cyborg Score thesis

Early-stage antifungal biotech with promising novel mechanism but pre-commercial status and near-term cash concerns require...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals / Antifungal Therapeutics
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest SCYNEXIS, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for SCYNEXIS, Inc.

AskCyborg analysts argue the bull and bear cases for SCYNEXIS, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
SCYNEXIS, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

SCYNEXIS, Inc. Overview

Pro stress-test →

SCYNEXIS is a biotechnology company committed to positively impacting patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The company offers BREXAFEMME for vulvovaginal candidiasis treatment, with ibrexafungerp as its lead candidate for invasive candidiasis, aspergillosis, and resistant fungal infections.

Strategic Profile

Pro stress-test →

SCYNEXIS develops fungerps, a novel class of triterpenoid antifungal agents distinct from traditional glucan synthase inhibitors. The company has licensing partnerships with GlaxoSmithKline, Merck Sharp & Dohme, Hansoh, R-Pharm, and Cypralis for development and commercialization of ibrexafungerp globally.

Competitive Landscape

Pro stress-test →

SCYNEXIS competes in the antifungal therapeutics space against established antifungals and emerging competitors. The company's competitive advantage lies in ibrexafungerp's novel mechanism of action effective against drug-resistant pathogens. Major pharmaceutical partnerships with GSK, Merck, and others position it within larger industry ecosystems rather than as standalone competitor.

Industry Context

SCYNEXIS, Inc. operates in Biopharmaceuticals / Antifungal Therapeutics.

Key facts

Founded: 1999 · Headquarters: Jersey City, New Jersey · Employees: 28 · Revenue: $3.7M · Market cap: $31.5M

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on SCYNEXIS, Inc..

  • Ibrexafungerp represents a novel antifungal class with unique mechanism offering advantage in treating drug-resistant infections.
  • Wall Street consensus is bullish with 7 buy ratings, average 12-month price target of $30.29 (314% upside), but stock trades significantly below target.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • Feb 2025Participation in Guggenheim 6th Annual Biotechnology Conference in New York
  • 2024Significant revenue decline; shift to partnership-driven commercialization model
  • +1 moreTrack every material event for SCYNEXIS, Inc. as it happens. Explore monitoring →
Get alerted when SCYNEXIS, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Conventional AntifungalsTraditional azoles and polyenes for fungal infections→SCY-247Second-generation IV/oral triterpenoid antifungal in development→Emerging Antifungal ProgramsVarious preclinical antifungal candidates→

Compare SCYNEXIS, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

SCYNEXIS, Inc. operates in Biopharmaceuticals / Antifungal Therapeutics. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceuticals by Cyborg Score

Browse Biopharmaceuticals / Antifungal Therapeutics research →
NEW · MCP server

Ask your AI assistant about SCYNEXIS, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare SCYNEXIS, Inc. and its top competitor on Cyborg Score”
“What did SCYNEXIS, Inc. do this quarter?”
“Is SCYNEXIS, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does SCYNEXIS, Inc. do?+
SCYNEXIS is a biotechnology company committed to positively impacting patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The company offers BREXAFEMME ...
What is SCYNEXIS, Inc.'s Cyborg Score?+
SCYNEXIS, Inc. has a Cyborg Score of 4/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are SCYNEXIS, Inc.'s main competitors?+
Named competitors include Conventional Antifungals, SCY-247, Emerging Antifungal Programs. The full competitive landscape is in the AskCyborg report.
How can I get the full SCYNEXIS, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the SCYNEXIS, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track SCYNEXIS, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Halozyme Therapeutics, Inc.8Vera Therapeutics, Inc.7AbbVie Inc.7Amneal Pharmaceuticals, Inc.7Arcutis Biotherapeutics, Inc.7BioArctic AB7Biogen Inc.7Bristol-Myers Squibb Company7Immix Biopharma, Inc.7Innovent Biologics, Inc.Top companies in Biopharmaceuticals by Cyborg Score